5-Amino-1MQ Research Summary

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small, membrane-permeable molecule currently being studied for its potent ability to inhibit the enzyme Nicotinamide N-methyltransferase (NNMT). While often grouped with peptides in research circles, it is technically a small molecule derivative of methylquinolinium.

Mechanism of Action

The primary function of 5-Amino-1MQ is the selective inhibition of NNMT. This enzyme is predominantly found in fat tissue (adipocytes) and plays a critical role in energy metabolism.

• The NNMT Connection: When NNMT is overactive—often due to age or high-calorie diets—it consumes high amounts of S-adenosylmethionine (SAM) and reduces the availability of NAD+.

• Boosting NAD+: By blocking NNMT, 5-Amino-1MQ prevents the depletion of NAD+. Higher NAD+ levels stimulate the SIRT1 gene (often called the "longevity gene"), which enhances mitochondrial function and metabolic rate.

• Fat Metabolism: In research models, this inhibition forces cells to burn fat for energy more efficiently without requiring a change in food intake.

Key Research Benefits

• Weight Management: Studies in mice show significant reductions in white adipose tissue (body fat) and overall body weight.

• Muscle Preservation & Strength: Unlike standard calorie restriction, which can lead to muscle loss, 5-Amino-1MQ has been shown to increase muscle contractility and grip strength. One study noted a 60% increase in grip strength when combined with exercise.

• Anti-Aging Properties: Through SIRT1 activation, it supports cellular repair and may reduce the risk of metabolic conditions like Type II diabetes and atherosclerosis.

• Energy & Recovery: Researchers observe improved mitochondrial efficiency, leading to higher sustained energy levels and faster recovery from physical exertion.

Research Protocol (50 mg Vial)

This protocol is designed for subcutaneous administration to maximize bioavailability compared to oral versions.

Reconstitution Guide

To achieve a standard concentration, the 50 mg lyophilized (freeze-dried) powder is typically mixed with 4.0 mL of Bacteriostatic Water.

• Resulting Concentration: 12.5 mg per 1 mL.

• Syringe Measurement: On a standard U-100 insulin syringe, 10 units = 1.25 mg.

Suggested Research Schedule

PhaseDaily DosageSyringe Units (0.01ml/unit)

Days 1–2 (Tolerance)2.5 mg (Once Daily)20 Units

Days 3+ (Standard)5 mg (Once Daily)40 Units

Alternative (Split)2.5 mg (Twice Daily)20 Units (AM) / 20 Units (PM)

• Timing: Research suggests a morning administration is most effective. Because the half-life is approximately 4–7 hours, splitting the dose (BID) may maintain more stable enzyme inhibition.

Storage & Handling

• Lyophilized (Powder): Store in a freezer at -20°C for long-term stability (up to 2 years).

• Reconstituted (Liquid): Must be refrigerated at 2–8°C. Use within 4 weeks for maximum potency.

• Handling: Do not shake the vial after adding water; gently swirl until the solution is clear.

SAHPRA DISCLAIMER:

This product has not been evaluated by the South African Health Products Regulatory Authority (SAHPRA). This product is not intended to diagnose, treat, cure, or prevent any disease.

RESEARCH USE ONLY